• Featured Product
  • KD/KO Validated

Alpha Galactosidase A Polyclonal antibody

Alpha Galactosidase A Polyclonal Antibody for WB, IP, IHC, ELISA

Host / Isotype

Rabbit / IgG


human, rat





Cat no : 15428-1-AP


Alpha D galactosidase A, Alpha galactosidase A, galactosidase, alpha

Tested Applications

Positive WB detected inMCF-7 cells, HEK-293 cells, HeLa cells
Positive IP detected inHEK-293 cells
Positive IHC detected inhuman liver cancer tissue, human liver tissue, mouse liver tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:3000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:250-1:1000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

15428-1-AP targets Alpha Galactosidase A in WB, IP, IHC, ELISA applications and shows reactivity with human, rat samples.

Tested Reactivity human, rat
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Alpha Galactosidase A fusion protein Ag7609
Full Name galactosidase, alpha
Calculated Molecular Weight 49 kDa
Observed Molecular Weight 46-50 kDa
GenBank Accession NumberBC002689
Gene Symbol GLA
Gene ID (NCBI) 2717
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

GLA (Alpha-galactosidase A), also named as Melibiase or Agalsidase, belongs to the glycosyl hydrolase 27 family. It catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. The deficient activity of GLA can cause Fabry disease which is an X-linked inborn error of glycosphingolipid metabolis (PMID: 19287194). Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease (PMID: 20398385). In humans, GLA is synthesized as a 50 kDa precursor, which is further processed to a 46 kDa mature form of the protein (PMID: 9883849, 19387866). It also has a homodimer form with the molecular mass of 110 kDa (PMID: 17287429).


Product Specific Protocols
WB protocol for Alpha Galactosidase A antibody 15428-1-APDownload protocol
IHC protocol for Alpha Galactosidase A antibody 15428-1-APDownload protocol
IP protocol for Alpha Galactosidase A antibody 15428-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



J Extracell Vesicles

Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.

Authors - Joaquin Seras-Franzoso
  • KO Validated

Orphanet J Rare Dis

Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.

Authors - Wladimir Mauhin